1. Microvascular invasion of single small hepatocellular carcinoma ≤3 cm: Predictors and optimal treatments
   Yo-ichi Yamashita et al, 2018, Ann Gastroenterol Surg CrossRef
2. Antitumor Effects and Delivery Profiles of Menahydroquinone-4 Prodrugs with Ionic or Nonionic Promoiety to Hepatocellular Carcinoma Cells
   Shuichi Setoguchi et al, 2018, Molecules CrossRef
3. Vascular Endothelial Growth Factor Level as A Predictor of Hepatocellular Carcinoma in Liver Cirrhosis Patients
   Benyamin Lukito et al, 2014, Indones Biomed J CrossRef
4. Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma
   Kazuomi Ueshima et al, 2011, Dig Dis CrossRef
5. Molecular Targeted Therapy for Hepatocellular Carcinoma: Bench to Bedside
   Masatoshi Kudo, 2011, Dig Dis CrossRef
6. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma
   Gabriele Ricco et al, 2020, CBM CrossRef
7. Enhanced Antitumor Effects of Novel Intracellular Delivery of an Active Form of Menaquinone-4, Menahydroquinone-4, into Hepatocellular Carcinoma
   Shuichi Setoguchi et al, 2015, Cancer Prev Res CrossRef
8. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib
   Kenichiro Kodama et al, 2019, Oncology CrossRef
9. Predictors of Microvascular Invasion in Hepatocellular Carcinoma
   Yo-ichi Yamashita et al, 2015, Dig Dis CrossRef
10. Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma
    Tatsuya Taniguchi et al, 2017, Digestion CrossRef
11. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
    Teiji Kuzuya et al, 2022, Oncology CrossRef
12. Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.
    Atsushi Hiraoka, 0 CrossRef
13. Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma
    Masatoshi Kudo, 2024, Liver Cancer CrossRef
14. Tumor Stroma, Desmoplasia, and Stromagenesis
    Arthur Zimmermann, 2016 CrossRef
15. Menahydroquinone-4 Prodrug: A Promising Candidate Anti-Hepatocellular Carcinoma Agent
    Munechika Enjoji et al, 2015, Diseases CrossRef
16. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma
    Teiji Kuzuya et al, 2024, Current Oncology CrossRef